NLS Merck

Danish biotech company Symphogen once again has its lead asset in its portfolio, experimental cancer drug Sym004, three years after it partnered with Merck on a $625 million deal for its development. The two companies said recently that they have ended their collaboration, with Symphogen saying it hopes to now turn itself into a standalone […]

Nuevolution A/S has announced that it has entered an exclusive license agreement with a subsidiary of Merck & Co., Inc. The agreement involves small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development. Under terms of the agreement, Merck will gain exclusive rights for the further development and […]

A multi-billion kroner agreement on a new pain-relief medication has been signed between the Norwegian innovation company, Inven2, and the pharmaceuticals giant, Merck. Public funding has played an important role in the Norwegian researchers’ success. The agreement confirms the vast potential of Norwegian health research. There are many outstanding researchers carrying out innovative basic and […]

Merck & Co plans to cut another 8,500 jobs. Merck expects to realize $1 billion by the end of 2014. Most of savings are expected to come from marketing and administrative expenses and research and development. Company shares rose $1.13, or 2.4 percent, to close at $48.74. Merck’s stock is up about 19 percent this […]

Merck & Co has licensed its experimental cancer drug to AstraZeneca for a $50 million upfront fee. Under the terms of agreement Merck will also be eligible to receive future payments related to development and regulatory milestones as well as tiered royalties. The drug called MK-1775 is currently in mid-stage trials in combination with standard-of-care […]